AbbVie’s Etentamig: A Next-Generation Bispecific Engager Set to Redefine Multiple Myeloma Treatment

September 6, 2026

Fierce Biotech USA

Overview

AbbVie has announced positive Phase 3 clinical trial results for etentamig, a second-generation bispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM). Targeting BCMA and CD3, etentamig demonstrated significant improvements in objective response rate (ORR) and progression-free survival (PFS) alongside a favorable safety profile, notably with reduced rates of cytokine release syndrome (CRS) and infections. Its potential for once-monthly, outpatient administration marks a significant advancement in patient convenience and access to advanced immunotherapies.

In Depth

Background

Multiple myeloma is a type of blood cancer, and new treatment options are continually sought for patients with relapsed or refractory disease. While previous T-cell engagers have been effective, they often required intensive management of severe side effects such as cytokine release syndrome and neurotoxicity, often necessitating strict inpatient monitoring. Etentamig’s improved safety profile and simplified once-monthly dosing regimen have the potential to significantly alter the RRMM treatment paradigm. This represents a meaningful advancement in both reducing patient burden and optimizing healthcare system resource utilization.

Key Findings

AbbVie announced positive results from a Phase 3 clinical trial for its bispecific T-cell engager, etentamig, in patients with relapsed/refractory multiple myeloma (RRMM). Etentamig met its primary endpoints, demonstrating improvements in both objective response rate (ORR) and progression-free survival (PFS). This second-generation bispecific T-cell engager, which targets B-cell maturation antigen (BCMA) and CD3, also showed a favorable safety profile with lower rates of cytokine release syndrome (CRS) and infections compared to previous T-cell engagers. These results represent a significant step towards providing a new, safer, and more effective treatment option for RRMM patients.

Etentamig is engineered to bind simultaneously to BCMA, highly expressed on multiple myeloma cells, and CD3, expressed on immune effector T-cells. This dual targeting mechanism brings T-cells into close proximity with tumor cells, inducing a cancer-specific immune response. The Phase 3 trial evaluated etentamig on a once-monthly dosing schedule, yielding data that suggests the treatment could be administered in outpatient and community-based settings. This convenience is a critical factor for improving patient quality of life and expanding access to care. The reduced incidence of CRS and infections in its safety profile is a major advantage for clinicians managing this potent therapy.

The positive Phase 3 results for etentamig pave the way for a regulatory submission, with future discussions with regulatory authorities keenly anticipated. If approved, this drug could become a groundbreaking therapeutic option for RRMM patients, particularly as its outpatient administration potential would broaden access to advanced immunotherapies for a larger population. Furthermore, the improved safety profile may expand the applicability of BiTE therapies to other hematologic malignancies and solid tumors. This advancement is expected to contribute substantially to improving long-term patient prognosis and quality of life.

Source: https://www.fiercebiotech.com/biotech/abbvies-bispecific-t-cell-engager-shows-promise-ph-3-multiple-myeloma-trial

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.